Emerging Therapies for Sensorineural Hearing Loss

Otology and Neurotology

Volumn 38, Issue 6, 2017, Pages 792-803

  Crowson, Matthew Gordon ^a   Hertzano, Ronna ^a,b   Tucci, Debara L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Hearing loss; Molecular therapy

Indexed keywords

ANIMAL; HUMAN; OTORHINOLARYNGOLOGY; PERCEPTION DEAFNESS; PROCEDURES; TRENDS;

ANIMALS; HEARING LOSS, SENSORINEURAL; HUMANS; OTOLARYNGOLOGY;

EID: 85017178680     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0000000000001427     Document Type: Article

References (128)

1. World Health Organization. Estimates. Prevention of Blindness and Deafness. Available at: http://www.who.int/pbd/deafness/esti-mates/en/. Accessed July 9, 2016.
2. Wake M, Hughes EK, Poulakis Z, Collins C, Rickards FW. Outcomes of children with mild-profound congenital hearing loss at 7 to 8 years: A population study. Ear Hear 2004;25:1-8.
3. Wake M, Hughes EK, Collins CM, Poulakis Z. Parent-reported health-related quality of life in children with congenital hearing loss: A population study. Ambul Pediatr 2004;4:411-7.
4. Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 1998;19:339-54.
5. Borton SA, Mauze E, Lieu JEC. Quality of life in children with unilateral hearing loss: a pilot study. Am J Audiol 2010;19:61-72.
6. Culbertson JL, Gilbert LE. Children with unilateral sensorineural hearing loss: cognitive, academic, and social development. Ear Hear 1986;7:38-42.
7. Nasralla HR, Bento RF, Valéria M, Gof S, Magalhaes AT. Important factors in the cognitive development of children with hearing impairment: Case studies of candidates for cochlear implants. Int Arch Otorhinolaryngol 2014;18:357-61.
8. Carlsson P-I, Hjaldahl J, Magnuson A, et al. Severe to profound hearing impairment: quality of life, psychosocial consequences and audiological rehabilitation. Disabil Rehabil 2015;37:1849-56.
9. Liljas AEM, Wannamethee SG, Papacosta O, et al. Social and lifestyle characteristics and burden of ill-health associated with self-reported hearing and vision impairments in older men in the British community: a cross-sectional study. Lancet 2014;384:S45.
10. Dalton DS, Cruickshanks KJ, Klein BEK, Klein R, Wiley TL, Nondahl DM. The impact of hearing loss on quality of life in older adults. Gerontologist 2003;43:661-8.
11. Mulrow CD, Aguilar C, Endicott JE, et al. Quality-of-life changes and hearing impairment a randomized trial quality-of-life changes and hearing impairment. A randomized trial. Ann Intern Med 1990;113:188-94.
12. Cruickshanks KJ, Tweed TS, Wiley TL, et al. The 5-year incidence and progression of hearing loss: the epidemiology of hearing loss study. Arch Otolaryngol Head Neck Surg 2003;129:1041-6.
13. Cruickshanks KJ, Wiley TL, Tweed TS, et al. Prevalence of hearing loss in older adults in Beaver Dam, Wisconsin. Am J Audiol 1998;148:879-86.
14. Bermingham NA. Math1: An essential gene for the generation of inner ear hair cells. Science 1999;284:1837-41.
15. Chen P, Johnson JE, Zoghbi HY, Segil N. The role of Math1 in inner ear development: Uncoupling the establishment of the sensory primordium from hair cell fate determination. Development 2002;129:2495-505.
16. Woods C, Montcouquiol M, Kelley MW. Math1 regulates development of the sensory epithelium in the mammalian cochlea. Nat Neurosci 2004;7:1310-8.
17. Zheng JL, Gao WQ. Overexpression of Math1 induces robust production of extra hair cells in postnatal rat inner ears. Nat Neurosci 2000;3:580-6.
18. Shou J, Zheng JL, Gao WQ. Robust generation of new hair cells in the mature mammalian inner ear by adenoviral expression of Hath1. Mol Cell Neurosci 2003;23:169-79.
19. Kawamoto K, Ishimoto S-I, Minoda R, Brough DE, Raphael Y. Math1 gene transfer generates new cochlear hair cells in mature guinea pigs in vivo. J Neurosci 2003;23:4395-400.
20. Izumikawa M, Minoda R, Kawamoto K, et al. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. Nat Med 2005;11:271-6.
21. Izumikawa M, Batts SA, Miyazawa T, Swiderski DL, Raphael Y. Response of the flat cochlear epithelium to forced expression of Atoh1. Hear Res 2008;240:52-6.
22. Merchant SN, Adams JC, Nadol JB. Pathology and pathophysi-ology of idiopathic sudden sensorineural hearing loss. Otol Neuro-tol 2005;26:151-60.
23. Hinojosa R, Marion M. Histopathology of profound sensorineural deafness. Ann N Y Acad Sci 1983;405:459-84.
24. U.S. National Institutes of Health. Safety, Tolerability and Efficacy for CGF166 in Patients With Bilateral Severe-to-profound Hearing Loss. ClinicalTrials.gov. Available at: http://clinical-trials.gov/show/NCT02132130. Published 2016. Accessed July 5, 2016.
25. Lalwani AK, Jero J, Mhatre AN. Current issues in cochlear gene transfer. Audiol Neurootol 2002;7:146-51.
26. Chien WW, McDougald DS, Roy S, Fitzgerald TS, Cunningham LL. Cochlear gene transfer mediated by adeno-associated virus: Comparison of two surgical approaches. Laryngoscope 2015;125: 2557-64.
27. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update. Physiol Rev 2012;92:689-737.
28. Coffey ET. Nuclear and cytosolic JNK signalling in neurons. Nat Rev Neurosci 2014;15:285-99.
29. Wong ACY, Ryan AF. Mechanisms of sensorineural cell damage, death and survival in the cochlea. Front Aging Neurosci 2015;7:1-15.
30. Kyriakis JM, Banerjee P, Nikolakaki E, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994;369:156-60.
31. Wang J, Ruel J, Ladrech S, Bonny C, van de Water TR, Puel J-L. Inhibition of the c-Jun N-terminal kinase-mediated mitochondrial cell death pathway restores auditory function in sound-exposed animals. Mol Pharmacol 2007;71:654-66.
32. Dinh CT, Goncalves S, Bas E, Van De Water TR, Zine A. Molecular regulation of auditory hair cell death and approaches to protect sensory receptor cells and/or stimulate repair following acoustic trauma. Front Cell Neurosci 2015;9:96.
33. Meltser I, Tahera Y, Canlon B. Differential activation of mitogen-activated protein kinases and brain-derived neurotrophic factor after temporary or permanent damage to a sensory system. Neuro-science 2010;165:1439-46.
34. Alagramam KN, Stepanyan R, Jamesdaniel S, Chen DH-C, Davis RR. Noise exposure immediately activates cochlear mitogen-activated protein kinase signaling. Noise Health 1974;16:400-9.
35. Tabuchi K, Nishimura B, Nakamagoe M, Hayashi K, Nakayama M, Hara A. Ototoxicity: mechanisms of cochlear impairment and its prevention. Curr Med Chem 2011;18:4866-71.
36. Scarpidis U, Madnani D, Shoemaker C, et al. Arrest of apoptosis in auditory neurons: implications for sensorineural preservation in cochlear implantation. Otol Neurotol 2003;24:409-17.
37. Wang J, Van De Water TR, Bonny C, de Ribaupierre F, Puel JL, Zine A. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci 2003;23:8596-607.
38. Eshraghi AA, He J, Mou CH, et al. D-JNKI-1 treatment prevents the progression of hearing loss in a model of cochlear implantation trauma. Otol Neurotol 2006;27:504-11.
39. Sugahara K, Rubel EW, Cunningham LL. JNK signaling in neomycin-induced vestibular hair cell death. Hear Res 2006;221: 128-35.
40. U.S. National Institutes of Health. AM-111 for the treatment of acute inner ear hearing loss. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT02561091. Accessed July 9, 2016.
41. Auris Medical. AM-111 for the treatment of acute inner ear hearing loss. Available at: http://www.aurismedical.com/prod-uct-candidates/am-111. Published 2015. Accessed May 7, 2016.
42. Coleman JKM, Littlesunday C, Jackson R, Meyer T. AM-111 protects against permanent hearing loss from impulse noise trauma. Hear Res 2007;226:70-8.
43. Barkdull GC, Hondarrague Y, Meyer T, Harris JP, Keithley EM. AM-111 reduces hearing loss in a guinea pig model of acute labyrinthitis. Laryngoscope 2007;117:2174-82.
44. Omotehara Y, Hakuba N, Hato N, Okada M, Gyo K. Protection against ischemic cochlear damage by intratympanic administration of AM-111. Otol Neurotol 2011;32:1422-7.
45. Grindal TC, Sampson EM, Antonelli PJ. AM-111 prevents hearing loss from semicircular canal injury in otitis media. Laryngoscope 2010;120:178-82.
46. Auris Medical. AM-111 Acute Hearing Loss Therapy Fact Sheet. Available at: http://www.aurismedical.com/images/auris/down-loads/auris-factsheet-AM111.pdf. Published 2015. Accessed May 7, 2016.
47. Suckfuell M, Canis M, Strieth S, Scherer H, Haisch A. Intra-tympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized phase I/II study. Acta Otolaryngol 2007;127:938-42.
48. Rahman K. Studies on free radicals, antioxidants, and co-factors. Clin Interv Aging 2007;2:219-36.
49. Henderson D, Bielefeld EC, Harris KC, Hu BH. The role of oxidative stress in noise-induced hearing loss. Ear Hear 2006;27:1-19.
50. Yang C-H, Schrepfer T, Schacht J. Age-related hearing impairment and the triad of acquired hearing loss. Front Cell Neurosci 2015;9:276.
51. Campbell KCM, Meech RP, Rybak LP, Hughes LF. The effect of D-methionine on cochlear oxidative state with and without cis-platin administration: mechanisms of otoprotection. J Am Acad Audiol 2003;14:144-56.
52. Vogt W. Oxidation of methionyl residues in proteins: Tools, targets, and reversal. Free Radic Biol Med 1995;18:93-105.
53. Campbell KCM, Meech RP, Klemens JJ, et al. Prevention of noise-and drug-induced hearing loss with d-methionine. Hear Res 2007;226:92-103.
54. Campbell KCM, Meech RP, Rybak LP, Hughes LF. D-Methionine protects against cisplatin damage to the stria vascularis. Hear Res 1999;138:13-28.
55. Campbell KCM, Rybak LP, Meech RP, Hughes L. D-Methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res 1996;102:90-8.
56. Kopke RD, Coleman JKM, Liu J, Campbell KCM, Riffenburgh RH. Enhancing intrinsic cochlear stress defenses to reduce noise-induced hearing loss. Laryngoscope 2002;112:1515-32.
57. Sha SH, Schacht J. Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-meth-ionine is a potential protectant. Hear Res 2000;142:34-40.
58. Samson J, Wiktorek-Smagur A, Politanski P, et al. Noise-induced time-dependent changes in oxidative stress in the mouse cochlea and attenuation by d-methionine. Neuroscience 2008;152:146-50.
59. Campbell K, Claussen A, Meech R, Verhulst S, Fox D, Hughes L. D-methionine (d-met) significantly rescues noise-induced hearing loss: Timing studies. Hear Res 2011;282:138-44.
60. U.S. National Institutes of Health. Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT01345474. Published 2015. Accessed May 7, 2016.
61. Wells TS, Seelig AD, Ryan MA, et al. Hearing loss associated with US military combat deployment. Noise Heal 2015;17:34-42.
62. Orsello CA, Moore JE, Reese C. Sensorineural hearing loss incidence among U.S. military aviators between 1997 and 2011. Aviat Sp Environ Med 2013;84:975-9.
63. Alamgir H, Tucker DL, Kim S-Y, et al. Economic burden of hearing loss for the U.S. military: A proposed framework for estimation. Mil Med 2016;181:301-6.
64. Vries N De, Flora S De. N-Acetyl-cysteine. Cell Biochem 1993;277:270-7.
65. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine:its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Rad Biol Med 1989;6:593-7.
66. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Review molecular mechanisms of N-acetylcysteine actions cellular and molecular life sciences review molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci Rev 2003;60:6-20.
67. Kopke R, Bielefeld E, Liu J, et al. Prevention of impulse noise-induced hearing loss with antioxidants. Acta Otolaryngol 2005;125:235-43.
68. Ewert DL, Lu J, Li W, Du X, Floyd R, Kopke R. Antioxidant treatment reduces blast-induced cochlear damage and hearing loss. Hear Res 2012;285:29-39.
69. Lorito G, Giordano P, Petruccelli J, Martini A, Hatzopoulos S. Different strategies in treating noiseinduced hearing loss with N-acetylcysteine. Med Sci Monit 2008;14:BR159-64.
70. Duan M, Qiu J, Laurell G, Olofsson A, Counter SA, Borg E. Dose and time-dependent protection of the antioxidant N-L-acetylcysteine against impulse noise trauma. Hear Res 2004;192: 1-9.
71. Motalebi Kashani M, Saberi H, Hannani M. Prevention of acoustic trauma-induced hearing loss by N-acetylcysteine administration in rabbits. Arch trauma Res 2013;1:145-50.
72. Wu HP, Hsu CJ, Cheng TJ, Guo YL. N-acetylcysteine attenuates noise-induced permanent hearing loss in diabetic rats. Hear Res 2010;267:71-7.
73. Lorito G, Giordano P, Prosser S, Martini A, Hatzopoulos S. Noise-induced hearing loss: a study on the pharmacological protection in the Sprague Dawley rat with N-acetyl-cysteine. Acta Otorhino-laryngol Ital 2006;26:133-9.
74. Coleman JKM, Kopke RD, Liu J, et al. Pharmacological rescue of noise induced hearing loss using N-acetylcysteine and acetyl-l-carnitine. Hear Res 2007;226:104-13.
75. Fetoni AR, Ralli M, Sergi B, Parrilla C, Troiani D, Paludetti G. Protective effects of N-acetylcysteine on noise-induced hearing loss in guinea pigs. Acta Otorhinolaryngol Ital 2009;29: 70-5.
76. Hamernik RP, Qiu W, Davis B. The effectiveness of N-acetyl-l-cysteine (l-NAC) in the prevention of severe noise-induced hearing loss. Hear Res 2008;239:99-106.
77. Choi C-H, Du X, Floyd RA, Kopke RD. Therapeutic effects of orally administrated antioxidant drugs on acute noise-induced hearing loss. Free Radic Res 2014;48:264-72.
78. Klein M, Koedel U, Pfister HW, Kastenbauer S. Meningitis-associated hearing loss: Protection by adjunctive antioxidant therapy. Ann Neurol 2003;54:451-8.
79. Ding Dalian, Jiang Haiyan, Chen Guang-Di, et al. N-acetyl-cysteine prevents age-related hearing loss and the progressive loss of inner hair cells in g-glutamyl transferase 1 deficient mice. Aging (Albany NY) 2016;8:730-50.
80. Yang WP, Hu BH, Chen GD, Bielefeld EC, Henderson D. Protective effect of N-acetyl-L-cysteine (L-NAC) against styrene-induced cochlear injuries. Acta Otolaryngol 2009;129: 1036-43.
81. Eshraghi AA, Roell J, Shaikh N, et al. A novel combination of drug therapy to protect residual hearing post cochlear implant surgery. Acta Otolaryngol 2016;6489:1-5.
82. Eastwood H, Pinder D, James D, et al. Permanent and transient effects of locally delivered n-acetyl cysteine in a guinea pig model of cochlear implantation. Hear Res 2010;259:24-30.
83. Doosti A, Lotfi Y, Moossavi A, Bakhshi E, Talasaz AH, Hoorzad A. Comparison of the effects of N-acetyl-cysteine and ginseng in prevention of noise induced hearing loss in male textile workers. Noise Health 2014;16:223-7.
84. Kopke R, Slade MD, Jackson R, et al. Efficacy and safety of N-acetylcysteine in prevention of noise induced hearing loss: A randomized clinical trial. Hear Res 2015;323:40-50.
85. Angeli SI, Abi-Hachem RN, Vivero RJ, Telischi FT, Machado JJ. L-N-Acetylcysteine treatment is associated with improved hearing outcome in sudden idiopathic sensorineural hearing loss. Acta Otolaryngol 2012;132:369-76.
86. U.S. National Institutes of Health. NAC to Prevent Cisplatin-induced Hearing Loss. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT02094625. Published 2016. Accessed May 7, 2016.
87. U.S. National Institutes of Health. Protective Effect of N-acetyl-cysteine Against From Ototoxicity This. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT01271088. Published 2011. Accessed May 7, 2016.
88. Lin C, Wu J, Shih T, et al. N-Acetyl-cysteine against noise-induced temporary threshold shift in male workers. Hear Res 2010;269:42-7.
89. Rybak LP. Cis-platinum associated hearing loss. J Laryngol Otol 1981;95:745-7.
90. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, Bagby GC. High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol Head Neck Surg 1993;119: 661-6.
91. Clerici WJ, Hensley K, DiMartino DL, Butterfield DA. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear Res 1996;98:116-24.
92. Rybak LP, Whitworth C, Somani S. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope 1999;109:1740-4.
93. Lapchak PA, Zivin JA. Ebselen a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: Synergism with low-dose tissue plasminogen activator. Stroke 2003;34: 2013-8.
94. Ohinata Y, Yamasoba T, Schacht J, Miller JM. Glutathione limits noise-induced hearing loss. Hear Res 2000;146:28-34.
95. Kim SJ, Park C, Han AL, et al. Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells. Hear Res 2009;251:70-82.
96. Kil J, Pierce C, Tran H, Gu R, Lynch ED. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res 2007;226:44-51.
97. Lynch ED, Gu R, Pierce C, Kil J. Ebselen-mediated protection from single and repeated noise exposure in rat. Laryngoscope 2004;114:333-7.
98. Kil J. Efficacy of SPI-1005 for prevention of noise-induced hearing loss: Phase 2 clinical trial results. Otolaryngol Head Neck Surg 2011;33:7-16.
99. U.S. National Institutes of Health. SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT01451853. Published 2016. Accessed May 7, 2016.
100. U.S. National Institutes of Health. Otoprotection With SPI-1005 for Prevention of Temporary Auditory. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT01444846. Accessed July 9, 2016.
101. U.S. National Institutes of Health. Study to Evaluate the Safety and Pharmacokinetics of SPI-1005. ClinicalTrials.Gov. Available at: http://clinicaltrials.gov/show/NCT01452607. Published 2016. Accessed May 7, 2016.
102. U.S. National Institutes of Health. A Phase 2b Study of SPI-1005 to Reduce the Incidence, Severity, and Duration of Acute Noise Induced Hearing Loss (NIHL). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT02779192. Published 2016. Accessed May 7, 2016.
103. Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW. Cisplatin rescue therapy: Experience with sodium thiosul-fate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hem-atol 1990;10:353-65.
104. Elferink F, Van Der Vijgh WJF, Klein I, Pinedo HM. Interaction of cisplatin and carboplatin with sodium thiosulfate: Reaction rates and protein binding. Clin Chem 1986;32:641-5.
105. Muldoon LL, Pagel MA, Kroll RA, et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototox-icity without reduction of antitumor activity. Clin Cancer Res 2000;6:309-15.
106. Neuwelt EA, Brummett RE, Remsen LG, et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotec-tant against carboplatin-induced ototoxicity. Cancer Res 1996;56: 706-9.
107. Stocks RMS, Gould HJ, Bush AJ, Dudney BW, Pousson M, Thompson JW. Ototoxic protection of sodium thiosulfate: Daily vs constant infusion. Otolaryngol Head Neck Surg 2004;131:115-9.
108. Saito T, Zhang ZJ, Manabe Y, Ohtsubo T, Saito H. The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs. Eur Arch Otorhinolaryngol 1997;254:281-6.
109. Hochman J, Blakley BW, Wellman M, Blakley L. Prevention of aminoglycoside-induced sensorineural hearing loss. J Otolaryngol 2006;35:153-6.
110. Madasu R, Ruckenstein MJ, Leake F, Steere E, Robbins KT. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Arch Oto-laryngol Head Neck Surg 1997;123:978-81.
111. Ishikawa E, Sugimoto H, Hatano M, et al. Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer. Acta Otolaryngol 2015;135: 919-24.
112. Zuur CL, Simis YJ, Lansdaal PE, et al. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 2007;25:3759-65.
113. U.S. National Institutes of Health. Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT00716976. Published 2016. Accessed May 7, 2016.
114. Ries PW. Prevalence and characteristics of persons with hearing trouble: United States, 1990-91. Vital Health Stat 1994;10:1-75.
115. Nelson EG, Hinojosa R. Presbycusis: a human temporal bone study of individuals with downward sloping audiometric patterns of hearing loss and review of the literature. Laryngoscope 2006;116:1-12.
116. Menardo J, Tang Y, Ladrech S, et al. Oxidative stress, inflammation, and autophagic stress as the key mechanisms of premature age-related hearing loss in SAMP8 mouse cochlea. Antioxid Redox Signal 2012;16:263-74.
117. Syka J. The Fischer 344 rat as a model of presbycusis. Hear Res 2010;264:70-8.
118. Bielefeld EC, Coling D, Chen G Di, et al. Age-related hearing loss in the Fischer 344/NHsd rat substrain. Hear Res 2008;241:26-33.
119. Seidman MD, Ahmad N, Bai U. Molecular mechanisms of age-related hearing loss. Ageing Res Rev 2002;1:331-43.
120. Someya S, Prolla TA. Mitochondrial oxidative damage and apoptosis in age-related hearing loss. Mech Ageing Dev 2010;131: 480-6.
121. Someya S, Xu J, Kondo K, et al. Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis. Proc Natl Acad Sci USA 2009;106:19432-7.
122. Yamasoba T, Someya S, Yamada C, Weindruch R, Prolla TA, Tanokura M. Role of mitochondrial dysfunction and mitochon-drial DNA mutations in age-related hearing loss. Hear Res 2007;226:185-93.
123. Ohlemiller KK. Mechanisms and genes in human strial presby-cusis from animal models. Brain Res 2009;1277:70-83.
124. Han C, Someya S. Mouse models of age-related mitochondrial neurosensory hearing loss. Mol Cell Neurosci 2013;55:95-100.
125. Bottger EC, Schacht J. The mitochondrion: A perpetrator of acquired hearing loss. Hear Res 2013;303:12-9.
126. Clifford ARE, Hoffer M, Rogers AR. The genomic basis of noise-induced hearing loss: A literature review organized by cellular pathways. Otol Neurotol 2016;37:309-16.
127. Kujawa SG, Liberman MC. Synaptopathy in the noise-exposed and aging cochlea: Primary neural degeneration in acquired sensorineural hearing loss. Hear Res 2015;330:191-9.
128. Sly ADJ, Campbell AL, Uschakov AA, Saief AST, Lam AM, Leary ASJO. Applying neurotrophins to the round window rescues auditory function and reduces inner hair cell synaptopathy after noise-induced hearing loss. Otol Neurotol 2016;37:1223-30.